Dr. Mayumi Fujita and Dr. Charles Dinarello of the University Of Colorado School Of Medicine have identified a novel biomarker known as IL-37, and developed a method for the diagnosis, prognosis, and monitoring of inflammatory cancers. Using microarray to analyze peripheral blood, Drs. Fujita and Dinarello found expression of IL-37 to be differentially expressed in human melanoma blood. qRT-PCR analysis confirmed that IL-37 was up-regulated 3.4 fold in blood leukocytes of melanoma patients (average IL-37 expression in healthy samples is 0.00015). IL-37 expression increases so dramatically that a significant change is detectable in even Stage I patient samples.
The early stage sensitivity of IL-37 makes it an ideal front line detection method for melanoma.
This method of measuring IL-37 shows great promise as an early diagnostic and prognostic tool for early stage inflammatory cancers, including melanoma, leukemia, pancreatic, breast, ovarian, prostate, and lung. In addition, increased expression of IL-37 is detectable in blood, permitting a simple diagnostic measurement in body fluids, including blood, cultured whole blood, serum, plasma, cerebrospinal and cancer tissue.
To learn more and view relevant patent documents, please open this short, non-confidential summary. For more CU
technologies available for licensing, please visit our Tech Explorer site.
1 hour ago